Education
About Us
Working with TipRanks
Follow Us
Aspire Biopharma Holdings, Inc. (ASBP)
:ASBP
Total Valuation
Aspire Biopharma Holdings has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Aspire Biopharma Holdings has 49,525,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,525,970
Owned by Insiders0.04%
Owned by Institutions3.76%
Financial Efficiency
Aspire Biopharma Holdings’s return on equity (ROE) is 8.14 and return on invested capital (ROIC) is 1130.41%.
Return on Equity (ROE)8.14
Return on Assets (ROA)-84.72
Return on Invested Capital (ROIC)1130.41%
Return on Capital Employed (ROCE)2.01
Revenue Per Employee0.00
Profits Per Employee-654.94K
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aspire Biopharma Holdings is ―. Aspire Biopharma Holdings’s PEG ratio is -0.00039.
PE Ratio―
PS Ratio0.00
PB Ratio-61.61
Price to Fair Value-61.61
Price to FCF-357.83
Price to Operating Cash Flow-6.43
PEG Ratio-0.00039
Income Statement
In the last 12 months, Aspire Biopharma Holdings had revenue of 0.00 and earned -12.54M in profits. Earnings per share was -1.52.
Revenue0.00
Gross Profit0.00
Operating Income-3.09M
Pretax Income-12.54M
Net Income-12.54M
EBITDA-11.65M
Earnings Per Share (EPS)-1.52
Cash Flow
In the last 12 months, operating cash flow was -2.95M and capital expenditures -4.00, giving a free cash flow of -2.95M billion.
Operating Cash Flow-2.95M
Free Cash Flow-2.95M
Free Cash Flow per Share-0.06
Dividends & Yields
Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.88
52-Week Price Change-97.23%
50-Day Moving Average0.43
200-Day Moving Average2.73
Relative Strength Index (RSI)46.20
Average Volume (3m)27.62M
Important Dates
Aspire Biopharma Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Aspire Biopharma Holdings as a current ratio of 0.09, with Debt / Equity ratio of -88.11%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap0.01
Net Debt to EBITDA-0.11
Interest Coverage Ratio-3.46
Taxes
In the past 12 months, Aspire Biopharma Holdings has paid 1.01K in taxes.
Income Tax1.01K
Effective Tax Rate>-0.01
Enterprise Valuation
Aspire Biopharma Holdings EV to EBITDA ratio is -8.26, with an EV/FCF ratio of -362.59.
EV to Sales0.00
EV to EBITDA-8.26
EV to Free Cash Flow-362.59
EV to Operating Cash Flow-362.59
Balance Sheet
Aspire Biopharma Holdings has $206.23K in cash and marketable securities with $8.47M in debt, giving a net cash position of -$8.27M billion.
Cash & Marketable Securities$206.23K
Total Debt$8.47M
Net Cash-$8.27M
Net Cash Per Share-$0.17
Tangible Book Value Per Share-$0.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―